# Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients

> **NCT00129376** · PHASE2 · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 63 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00129376
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-07
- **Final completion:** 2010-02
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2019-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129376, "Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00129376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*